Univariate analysis of 77 patients treated with rituximab
| Variable . | Univariate analysis . | |
|---|---|---|
| Event rate (%) . | P6-150 . | |
| Sex | ||
| M | 16/47 (34) | .03 |
| F | 5/30 (17) | |
| Age | ||
| 60 y or younger | 19/68 (28) | .99 |
| Older than 60 y | 2/9 (22) | |
| LDH | ||
| Yes | 6/11 (55) | .09 |
| No | 15/65 (23) | |
| Bulky | ||
| Yes | 7/23 (30) | .59 |
| No | 14/54 (26) | |
| Extra nodal sites other BM | ||
| Less than 2 | 18/71 (25) | .01 |
| 2 or more | 3/6 (50) | |
| BM infiltration | ||
| Yes | 16/56 (29) | .5 |
| No | 5/21 (24) | |
| Clinical response after CHOP | ||
| CR | 6/37 (16) | .01 |
| PR | 15/40 (38) | |
| IPI | ||
| 0 to 1 | 11/48 (23) | .29 |
| At least 2 | 10/28 (36) | |
| (PCR on BM at wk +12) | ||
| Yes | 12/31 (39) | .09 |
| No | 9/45 (20) | |
| (PCR+ on BM at wk +44) | ||
| Yes | 15/31 (48) | .001 |
| No | 6/45 (13) | |
| Variable . | Univariate analysis . | |
|---|---|---|
| Event rate (%) . | P6-150 . | |
| Sex | ||
| M | 16/47 (34) | .03 |
| F | 5/30 (17) | |
| Age | ||
| 60 y or younger | 19/68 (28) | .99 |
| Older than 60 y | 2/9 (22) | |
| LDH | ||
| Yes | 6/11 (55) | .09 |
| No | 15/65 (23) | |
| Bulky | ||
| Yes | 7/23 (30) | .59 |
| No | 14/54 (26) | |
| Extra nodal sites other BM | ||
| Less than 2 | 18/71 (25) | .01 |
| 2 or more | 3/6 (50) | |
| BM infiltration | ||
| Yes | 16/56 (29) | .5 |
| No | 5/21 (24) | |
| Clinical response after CHOP | ||
| CR | 6/37 (16) | .01 |
| PR | 15/40 (38) | |
| IPI | ||
| 0 to 1 | 11/48 (23) | .29 |
| At least 2 | 10/28 (36) | |
| (PCR on BM at wk +12) | ||
| Yes | 12/31 (39) | .09 |
| No | 9/45 (20) | |
| (PCR+ on BM at wk +44) | ||
| Yes | 15/31 (48) | .001 |
| No | 6/45 (13) | |
Log rank.
For abbreviations, see Table 1.